Effect of neuropathic pain on sphenopalatine ganglion block responses in persistent idiopathic facial pain

• Published in: Neurological research (New York) Vol. 45; no. 5; pp. 400 - 406
• Main Authors: Kaya, Samet Sancar, Çelik, Şeref, Akçaboy, Erkan Yavuz, Göksu, Hamit, Yıldız, Gökhan, Şahin, Şaziye
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 04-05-2023
• Subjects: Adult; atypical facial pain; block; Chronic Pain; DN4 questionnaire score; Facial Pain - therapy; fluoroscopic block; Humans; Lidocaine - therapeutic use; Middle Aged; Neuralgia - therapy; neuropathic pain; Persistent idiopathic facial pain; predictor; sphenopalatine ganglion; Sphenopalatine Ganglion Block - methods; neuropathic pain; atypical facial pain; block; predictor; fluoroscopic block; Persistent idiopathic facial pain; sphenopalatine ganglion; DN4 questionnaire score
• ISSN: 0161-6412; 1743-1328
• DOI: 10.1080/01616412.2022.2149187

Management of persistent idiopathic facial pain (PIFP) can be challenging. Sphenopalatine ganglion (SPG) has been the target for the interventional treatment of many facial pain syndromes. However, possible factors that may affect SPG block success are unknown. It was aimed to investigate the effect of neuropathic pain on SPG block outcomes in PIFP, which includes a heterogeneous patient group.
All of the patients underwent fluoroscopy-guided SPG block with an injection of 40 mg of 2% lidocaine and 8 mg of dexamethasone. The patients were assigned to 2 groups according to existence of neuropathic pain determined with the DN4 questionnaire score: 19 patients with neuropathic pain (Group 1) and 15 patients without neuropathic pain (Group 2). Preprocedural and postprocedural Visual Analog Scale (VAS) scores were compared between the 2 groups.
The mean age of the patients was 47.65 ± 6.50 years. The average pain duration was 52.95 ± 34.81 weeks. A significantly greater decrease was detected in the VAS scores at 1 week (p = 0.036) and 1 month (p < 0.001) in Group 1 when compared to Group 2. Moreover, the proportion of patients with >50% improvement in the VAS scores at 1 week (p = 0.012) and 1 month (P = 0.017) was significantly lower in Group 1 than in Group 2.
SPG block appears as a safe, effective, and rapid method to treat PIFP, especially in cases with neuropathic pain. Neuropathic pain may be a predictor for pain relief in interventional procedures targeting SPG in the treatment of PIFP.